Reactogenicity and Immunogenicity of Vaginal CNgp140 (SG06RS02)

This study has been terminated.
(IMP expired prior to completion of recruitment)
Sponsor:
Collaborators:
Bill and Melinda Gates Foundation
York Hospitals
Information provided by:
St George's, University of London
ClinicalTrials.gov Identifier:
NCT00637962
First received: March 11, 2008
Last updated: February 10, 2011
Last verified: February 2011
  Purpose

To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period.


Condition Intervention Phase
HIV Infections
Acquired Immune Deficiency Syndrome
Biological: HIV glycoprotein CN54gp140 (vaccine)
Biological: Carbopol 974
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Nine Vaginal Immunisations With HIV CN54gp140 Glycoprotein

Resource links provided by NLM:


Further study details as provided by St George's, University of London:

Primary Outcome Measures:
  • To determine the local and systemic safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period. [ Time Frame: 13 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • frequency of subjects mounting a cervico-vaginal IgA and IgG response to gp140 after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]
  • frequency of subjects mounting a serum IgG and IgA response to gp140 after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]
  • frequency of subjects with a T-cell response to gp140 in blood after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]
  • frequency of cellular responses to gp140 in cervical cells after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]

Enrollment: 23
Study Start Date: September 2007
Study Completion Date: January 2009
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active product
CN54gp140 + gel
Biological: HIV glycoprotein CN54gp140 (vaccine)
vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
Other Name: Previously designated ZM96gp140
Placebo Comparator: Gel alone
Gel alone
Biological: Carbopol 974
vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
Other Name: Carbapol gel

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • They are adult female volunteers, 18 to 45 years of age, who have signed an informed consent form following a detailed written explanation of participation in the protocol.
  • They are volunteers who are in good health as determined by medical history, physical examination and clinical judgement.
  • They are available for the duration of the study.
  • They are women who, if capable of becoming pregnant during the study, have agreed to have a pregnancy test immediately before immunisation, and to use appropriate contraception methods during the whole study period. Appropriate contraception shall include physician-prescribed oral hormonal agents, barrier contraceptives, regular and consistent use of condoms without spermicidal agents, or intrauterine devices only. Progesterone-only contraceptives are not suitable due to the lack of a regular menstrual cycle.
  • They have agreed not to undertake any vaginal practices other than receptive intercourse with a male or use of sanitary tampons during menses. Use of condoms without spermicidal agents is encouraged.
  • They have not donated blood during 3 months prior to study entry and agree to not donate for 3 months after the end of their participation in the study.

Exclusion Criteria:

  • They have hypersensitivity to any component of the vaccine used in this study.
  • They are found to be HIV antibody or HIV proviral DNA positive at the time of initial screening.
  • They have a known or suspected history of cervico-vaginal disease, malignancy or abnormality discovered at time of screening.
  • They present in the samples obtained at the screening visit:

    • a clinically significant amount of protein or haemoglobin in the urine sample, determined by urine dipstick.
    • a clinically significant abnormality in the haematological or biochemical assays.
    • Positive tests for Hepatitis B and/or C infection An abnormal value will be defined by the ranges quoted by The Doctors Laboratory for the Vaccine Institute site and Pathology Department, York Hospital for the York site.
  • They have a known or suspected impairment of lung, heart, liver, kidney, diseases, blood disorders or immune dysfunction.
  • They are receiving immunosuppressive therapy (including systemic steroids).
  • They are receiving any medications via vaginal route.
  • They have any acute infections (including fever greater than or equal to 38°C) or any chronic disease.
  • They present a current problem with substance abuse or with a history of substance abuse which, in the opinion of the investigator, might interfere with participation in the study.
  • They have any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
  • They have received an investigational agent within 3 months prior to study entry.
  • They cannot speak fluent English, or are planning to leave the area of the study site prior to the end of the study period, or are likely not to complete the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00637962

Locations
United Kingdom
St George's Vaccine Institute
London, England, United Kingdom, SW17 0RE
York Hospital
York, England, United Kingdom, YO31 7WA
Sponsors and Collaborators
St George's, University of London
Bill and Melinda Gates Foundation
York Hospitals
Investigators
Principal Investigator: David JM Lewis, MD St George's, University of London, UK
Principal Investigator: Charles Lacey, MD York Hospitals
Study Director: David JM Lewis, MD St George's, University of London, UK
  More Information

Additional Information:
No publications provided by St George's, University of London

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr David JM Lewis, Chief Investigator, St George's University of London
ClinicalTrials.gov Identifier: NCT00637962     History of Changes
Other Study ID Numbers: 2007-000781-20, 07/Q0803/29, 2007-000781-20
Study First Received: March 11, 2008
Last Updated: February 10, 2011
Health Authority: United Kingdom: Research Ethics Committee
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by St George's, University of London:
HIV
AIDS
Vaccine
intravaginal
mucosal
HIV Seronegativity

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Krestin
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Interferon Inducers
Radiation-Protective Agents
Protective Agents

ClinicalTrials.gov processed this record on August 28, 2014